Publications by authors named "Robert Fram"

Claim this Profile
R
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.
Myung-Ju Ahn, Angelo Delmonte, Sharmistha Ghosh, Maximilian Hochmair, Tsung-Ying Yang, Robert J Fram

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
Pasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, Jun Zhao, Juan Li, Robert J Fram

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
D Ross Camidge, Shunichi Sugawara, Masashi Kondo, Hye Ryun Kim, Myung-Ju Ahn, Robert J Fram

Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
Kiyotaka Yoh, Koichi Azuma, Hidetoshi Hayashi, Makoto Nishio, Kenichi Chikamori, Robert J Fram

Int J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants.
Michael J Hanley, Steven Zhang, Robert Griffin, Sean Xiaochun Zhu, Robert J Fram

Invest New Drugs· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobocertinib: Mechanism of action, clinical, and translational science.
Michael J Hanley, D Ross Camidge, Robert J Fram, Neeraj Gupta

Clin Transl Sci· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes.
Joshua F Zeidner, Flora Mazerolle, Jonathan Norton, Antoine Regnault, Fjoralba Kristo, Robert J Fram

Haematologica· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Lionel Adès, Larisa Girshova, Vadim A Doronin, María Díez-Campelo, David Valcárcel, Robert J Fram

Blood Adv· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Mikkael A Sekeres, Justin Watts, Atanas Radinoff, Montserrat Arnan Sangerman, Marco Cerrano, Robert J Fram

Leukemia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Mikkael A Sekeres, Justin Watts, Atanas Radinoff, Montserrat Arnan Sangerman, Marco Cerrano, Robert J Fram

Leukemia· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30.
Antoine Regnault, Farrah Pompilus, Anna Ciesluk, Flora Mazerolle, Rafael Bejar, Robert J Fram

J Patient Rep Outcomes· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States.
Jill A Bell, Aaron Galaznik, Marlo Blazer, Huai-Che Shih, Eileen Farrelly, Robert J Fram

Pharmacoecon Open· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Jill A Bell, Aaron Galaznik, Farrah Pompilus, Sara Strzok, Rafael Bejar, Robert J Fram

J Patient Rep Outcomes· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
Jill A Bell, Aaron Galaznik, Eileen Farrelly, Marlo Blazer, Sharanya Murty, Robert J Fram

Leuk Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care.
Jill A Bell, Aaron Galaznik, Marlo Blazer, Eileen Farrelly, Augustina Ogbonnaya, Robert J Fram

Leuk Lymphoma· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
Jill A Bell, Aaron Galaznik, Eileen Farrelly, Marlo Blazer, Sharanya Murty, Robert J Fram

Leuk Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review.
Jill A Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J Fram

Clin Lymphoma Myeloma Leuk· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Jill A Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J Fram

Clin Lymphoma Myeloma Leuk· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
Mark D Walsh, Suzan K Hanna, Jeremy Sen, Sumit Rawal, Carolina B Cabral, Robert J Fram

Clin Cancer Res· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.
Alexander V Yurkovetskiy, Robert J Fram

Adv Drug Deliv Rev· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A perspective on errors, bias, and interpretation in the forensic sciences and direction for continuing advancement.
Bruce Budowle, Maureen C Bottrell, Stephen G Bunch, Robert Fram, Diana Harrison

J Forensic Sci· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Scot Ebbinghaus, Eric Rubin, Evan Hersh, Lee D Cranmer, Peter L Bonate, Robert J Fram

Clin Cancer Res· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Casey Cunningham, Leonard J Appleman, Miora Kirvan-Visovatti, David P Ryan, Eileen Regan, Robert J Fram

Clin Cancer Res· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
Kenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, Noopur Raje, Shaji Kumar, Robert Fram

Oncogene· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinically relevant SCID-hu in vivo model of human multiple myeloma.
Pierfrancesco Tassone, Paola Neri, Daniel R Carrasco, Renate Burger, Victor S Goldmacher, Robert Fram

Blood· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis